Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 6
Submit an article Journal homepage
1,113
Views
1
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study

Hartmut GoldschmidtDivision of Multiple Myeloma, Universitatsklinikum Heidelberg, Heidelberg, Germany; Correspondence[email protected]
View further author information
,
Philippe MoreauDepartment of Hematology, University of Nantes, Nantes, France; View further author information
,
Heinz LudwigWilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; View further author information
,
Ruben NiesvizkyMultiple Myeloma Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA; View further author information
,
Wee-Joo ChngDepartment of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore and Cancer Science Institute of Singapore, National University of Singapore, Singapore; View further author information
,
Douglas JoshuaInstitute of Haematology, Royal Prince Alfred Hospital, the University of Sydney, Camperdown, New South Wales, Australia; View further author information
,
Katja WeiselDepartment of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, Universitatsklinikum Tubingen, Tubingen, Germany; View further author information
,
Andrew SpencerDivision of Blood Cancers, Alfred Health-Monash University, Melbourne, Victoria, Australia; View further author information
,
Robert Z. OrlowskiDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, The University of Texas, Houston, TX, USA; View further author information
,
Shibao FengAmgen, Inc, Thousand Oaks, CA, USA; View further author information
,
Karim S. IskanderAmgen, Inc, Thousand Oaks, CA, USA; View further author information
&
Meletios A. DimopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, GreeceView further author information
 show all
Pages 1364-1374 | Received 05 Jun 2017, Accepted 30 Aug 2017, Published online: 22 Sep 2017

References

  • SEER. 2016 Cancer Statistics Factsheets: Myeloma. National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed 6 October 2016.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
  • Millennium Pharmaceuticals Inc. Velcade (bortezomib) prescribing information. Cambridge (MA): Millennium Pharmaceuticals, Inc. 2015.
  • Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–440.
  • Merz M, Salwender H, Haenel M, et al. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica 2016;101:e485–e487.
  • Moreau P, Touzeau C. New data on subcutaneous bortezomib. Acta Haematol. 2015; 133:26–28.
  • National Comprehensive Cancer Network (NCCN) 2016. NCCN clinical practice guidelines in oncology. Multiple myeloma. Version 1. 2017. Available at: www.nccn.org/patients. Accessed on October 7, 2016.
  • Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32:95–103.
  • Jagannath S, Roy A, Kish J, et al. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. Expert Rev Hematol. 2016;9:707–717.
  • Onyx Pharmaceuticals Inc. Krypolis (carfilzomib) prescribing information. Thousand Oaks (CA): Onyx Pharmaceuticals, Inc. 2016.
  • Dimopoulos MA, Moreau P, Palumbo A, ENDEAVOR Investigators, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.
  • Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498.
  • Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012;97:1925–1928.
  • San-Miguel J, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–1206.
  • Palumbo A, Chanan-Khan A, Weisel K, CASTOR Investigators, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766.
  • Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood 2016;127:2833–2840.
  • Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia 2014;28:258–268.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.